Drug Discovery

Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications

Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications.

invoX Pharma completes acquisition of F-star Therapeutics for $161m

invoX Pharma, a UK-based biopharmaceutical company and a wholly-owned subsidiary of Sino Biopharmaceutical, has closed the acquisition of F-star Therapeutics, a clinical-stage biopharmaceutical company focusing on bispecific antibodies in immunotherapy.

Tempus, Pfizer partner for cancer drug development

Tempus has unveiled a multi-year strategic partnership with Pfizer for advancing the development of cancer drugs.

Alchemab, MDC receive grant to develop Huntington’s disease therapy

Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.

Gilgamesh raises funds to advance treatments for mental health

Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.

Innovent and LG Chem sign agreement for gout disease therapy Tigulixostat

Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.

Merck initiates cash tender offer to buy Imago BioSciences

Merck has initiated a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Imago BioSciences.

HitGen, Nitrase partner for library-based drug discovery

Chinese company HitGen has signed a research agreement with biopharmaceutical firm Nitrase Therapeutics to discover DNA-encoded library-based drug.

Rallybio, AbCellera partner to develop therapeutics for rare diseases

US-based biotechnology firm Rallybio has entered into a strategic alliance with AbCellera to discover, develop, and commercialise new antibody-based therapeutics for rare diseases.